Gosset Ownership
Private
Therapeutic Areas
Stage
Preclinical
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Modalities
Firefly Bio General Information
Firefly Bio has demonstrated in preclinical studies that its DACs can significantly reduce tumor volume at very low doses in both solid and liquid tumor models. The company is preparing to advance two co-lead programs toward clinical trials, supported by strong preclinical proof-of-concept data.[1][3]
Contact Information
Primary Industry
Biotech
Corporate Office
South San Francisco, California
United States
United States
Drug Pipeline
No pipeline data available
Key Partnerships
Versant Ventures’ Ridgeline Discovery Engine collaboration for incubation and early R&D[1][3]
Firefly Bio Funding
No funding data available
To view Firefly Bio's complete valuation and funding history, request access »